Literature DB >> 16385630

Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines.

Walter P Weber1, Chantal Feder-Mengus, Alberto Chiarugi, Rachel Rosenthal, Anca Reschner, Reto Schumacher, Paul Zajac, Heidi Misteli, Daniel M Frey, Daniel Oertli, Michael Heberer, Giulio C Spagnoli.   

Abstract

Production of indoleamine 2,3-dioxygenase (IDO) by tumor cells, leading to tryptophan depletion and production of immunosuppressive metabolites, may facilitate immune tolerance of cancer. IDO gene is also expressed in dendritic cells (DC) upon maturation induced by lipopolysaccarides or IFN. We investigated IDO gene expression in melanoma cell lines and clinical specimens as compared to mature DC (mDC). Furthermore, we explored effects of L-kynurenine (L-kyn) and 3-hydroxyanthranilic acid (3-HAA) on survival and antigen-dependent and independent proliferation of CD8(+) cells. We observed that IDO gene expression in cultured tumor cells and freshly excised samples is orders of magnitude lower than in mDC, providing highly efficient antigen presentation to CD8(+) T cells. Non toxic concentrations of L-kyn or 3-HAA did not significantly inhibit antigen-specific CTL responses. However, 3-HAA, but not L-kyn markedly inhibited antigen-independent proliferation of CD8(+) T cells induced by common receptor gamma-chain cytokines IL-2, -7 and -15. Our data suggest that CD8(+) T cell activation induced by antigenic stimulation, a function exquisitely fulfilled by mDC, is unaffected by tryptophan metabolites. Instead, in the absence of effective T cell receptor triggering, 3-HAA profoundly affects homeostatic proliferation of CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16385630     DOI: 10.1002/eji.200535616

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

1.  Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia.

Authors:  Giovanni Sais; Stephen Wyler; Tvrtko Hudolin; Irina Banzola; Chantal Mengus; Lukas Bubendorf; Peter J Wild; Hans H Hirsch; Tullio Sulser; Giulio C Spagnoli; Maurizio Provenzano
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 2.  Advancements in immune tolerance.

Authors:  Ping-Ying Pan; Junko Ozao; Zuping Zhou; Shu-Hsia Chen
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

3.  Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development.

Authors:  Jennifer E Cole; Nagore Astola; Adam P Cribbs; Michael E Goddard; Inhye Park; Patricia Green; Alun H Davies; Richard O Williams; Marc Feldmann; Claudia Monaco
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

Review 4.  Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.

Authors:  Edwin J Vazquez-Cintron; Ngozi R Monu; Alan B Frey
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

5.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

Review 6.  Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.

Authors:  Trevor W Stone; Caroline M Forrest; Nicholas Stoy; L Gail Darlington
Journal:  J Neural Transm (Vienna)       Date:  2011-06-22       Impact factor: 3.575

Review 7.  Targeting TDO in cancer immunotherapy.

Authors:  Cheng-Peng Yu; Yun-Lei Song; Zheng-Ming Zhu; Bo Huang; Ying-Qun Xiao; Da-Ya Luo
Journal:  Med Oncol       Date:  2017-03-29       Impact factor: 3.064

8.  HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells.

Authors:  Adriano Boasso; Jean-Philippe Herbeuval; Andrew W Hardy; Stephanie A Anderson; Matthew J Dolan; Dietmar Fuchs; Gene M Shearer
Journal:  Blood       Date:  2006-12-07       Impact factor: 22.113

Review 9.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.